Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Dok-7 Inhibitors

Dok-7 inhibitors are a class of chemical compounds that target the Dok-7 (Downstream of kinase 7) protein, which plays a crucial role in neuromuscular signaling and the formation of neuromuscular junctions (NMJs). Dok-7 is an adaptor protein that interacts with the muscle-specific kinase (MuSK) and is essential for MuSK-mediated signaling, which is critical for the proper development and maintenance of NMJs. These junctions are the sites where motor neurons communicate with muscle fibers to initiate muscle contraction. By activating MuSK, Dok-7 helps in the clustering of acetylcholine receptors on the muscle membrane, facilitating the transmission of neural signals to muscles. Inhibitors of Dok-7 work by interfering with its ability to interact with MuSK, thereby disrupting the signaling pathways necessary for NMJ formation and function.

The design of Dok-7 inhibitors involves identifying molecules that can specifically bind to regions of Dok-7 that are responsible for its interaction with MuSK or other proteins involved in the signaling cascade. These inhibitors function by preventing Dok-7 from activating MuSK, thereby blocking the downstream processes essential for NMJ assembly and maintenance. Structural studies of Dok-7 have been crucial in identifying the domains necessary for its function, allowing for the development of inhibitors that specifically target its activity without affecting other proteins in the pathway. Dok-7 inhibitors are valuable tools for researchers aiming to study the molecular mechanisms involved in neuromuscular signaling and junction formation. By inhibiting Dok-7, scientists can explore how this protein contributes to the precise coordination of muscle function and neural communication, gaining insights into the regulation of muscle development and maintenance at the molecular level.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Imatinib is a tyrosine kinase inhibitor that may indirectly affect Dok-7 by inhibiting kinases in related signaling pathways.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib, another tyrosine kinase inhibitor, could potentially influence Dok-7 activity by modulating receptor tyrosine kinase signaling.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

Erlotinib, an EGFR inhibitor, may have an indirect effect on Dok-7 through the inhibition of epidermal growth factor receptor signaling.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Sunitinib, a receptor tyrosine kinase inhibitor, could indirectly affect Dok-7 activity by targeting related signaling pathways.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Lapatinib, a dual EGFR and HER2 inhibitor, might influence Dok-7 indirectly through its action on these receptors.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib, a broad-spectrum kinase inhibitor, could potentially impact Dok-7 by targeting multiple kinases in associated signaling pathways.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

Trametinib, a MEK inhibitor, might indirectly influence Dok-7 activity through the MAPK/ERK pathway.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Gefitinib, an EGFR inhibitor, could indirectly affect Dok-7 through its effect on epidermal growth factor receptor signaling pathways.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Vandetanib, a receptor tyrosine kinase inhibitor, may have an indirect influence on Dok-7 by targeting kinases in related signaling cascades.